A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

As reported by Business News

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on Business News ↗

Market Samachar is a news aggregator. This article was originally published by Business News. Tap the button above to read the full story on their site.

CRYPTO Bitcoin price targets $78K as BTC holders defend 'strongest near-term support' Cointelegraph.com News
CRYPTO Bitcoin's wild days are over — and Trace Mayer says that's a good thing CoinDesk: Bitcoin, Ethereum, Crypto News and Price Data
GLOBAL In deeply red Oklahoma, minimum wage’s biggest 2026 election cycle fight is about to be decided CNBC
GLOBAL Australia extends measure that releases petrol and diesel from domestic reserves - Reuters Reuters
GLOBAL The SpaceX IPO is great for Elon Musk and terrible for you - The Verge The Verge
GLOBAL We did the math on Ken Griffin's pied-à-terre tax bill - Business Insider Business Insider
GLOBAL SpaceX awarded $6.45B in Space Force contracts ahead of IPO - TechCrunch TechCrunch
GLOBAL 5 economic signals suggest U.S. consumers are feeling the strain - CBS News CBS News

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

More from Market Samachar